Prospects for early investigational therapies for sickle cell disease

Expert Opinion on Investigational Drugs

Volumn 24, Issue 5, 2015, Pages 595-602

  Conran, Nicola ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Early investigational drugs; Pathophysiology; Sickle cell disease; Vaso occlusion

Indexed keywords

ANTISICKLING AGENT; HYDROXYUREA; NEW DRUG;

DISEASE COURSE; EXPERIMENTAL THERAPY; HUMAN; PATHOPHYSIOLOGY; REVIEW; SICKLE CELL ANEMIA; ANEMIA, SICKLE CELL; ANIMAL; DRUG DESIGN;

ANEMIA, SICKLE CELL; ANIMALS; DRUG DESIGN; DRUGS, INVESTIGATIONAL; HUMANS; HYDROXYUREA;

EID: 84927637660     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1012292     Document Type: Review

References (40)

1. Stuart MJ, Nagel RL. Sickle-cell disease. Lancet 2004;364(9442):1343-60
2. Piel FB, Tatem AJ, Huang Z, et al. Global migration and the changing distribution of sickle haemoglobin: a quantitative study of temporal trends between 1960 and 2000. Lancet Glob Health 2014;2(2):e80-9
3. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995;332(20):1317-22
4. McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol 2011;18(3):158-65
5. Kassim AA, DeBaun MR. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease. Expert Opin Pharmacother 2014;15(3):325-36
6. Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012;120(22):4285-91
7. Kutlar A, Swerdlow PS, Meiler SE, et al. Pomalidomide in sickle cell disease: Phase I study of a novel anti-switching agent. Blood 2013;122:abstract 777
8. dos Santos JL, Lanaro C, Lima LM, et al. Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. J Med Chem 2011;54(16):5811-19
9. Fard AD, Hosseini SA, Shahjahani M, et al. Evaluation of novel fetal hemoglobin inducer drugs in treatment of beta-hemoglobinopathy disorders. Int J Hematol Oncol Stem Cell Res 2013;7(3):47-54
10. Safo MK, Kato GJ. Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin. Hematol Oncol Clin North Am 2014;28(2):217-31
11. Niihara Y, Koh HA, Tran L, et al. A phase III study of L-glutamine therapy for Sickle cell anemia and sickle -0-thalassemia. Blood (ASH) 2014;124(21):abstract:86
12. Ataga KI, Reid M, Ballas SK, et al. Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a Phase III randomized, placebocontrolled, double-blind study of the gardos channel blocker senicapoc (ICA-17043). Br J Haematol 2011;153(1):92-104
13. Chang J, Patton JT, Sarkar A, et al. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood 2010;116(10):1779-86
14. Wun T, Styles L, DeCastro L, et al. Phase I study of the E-selectin inhibitor GMI 1070 in patients with sickle cell anemia. PLoS One 2014;9(7):e101301
15. Wun T, Telen MJ, Krishnamurti L, et al. Pan-selectin antagonist rivipansel (GMI-1070) reduces soluble E-selectin levels while improving clinical outcomes in SCD vaso-occlusive crisis. Blood (ASH) 2014;124:abstract:2704
16. Okpala I. Investigational selectin-targeted therapy of sickle cell disease. Expert Opin Investig Drugs 2015;24(2):229-38
17. Manwani DM, Chen C, Carullo V, et al. Vaso-occlusion-promoting neutrophil mac-1 integrin activation in human sickle cell crises is stabilized by a single dose of intravenous gammaglobulin. Blood (ASH) 2014;124:abstract:4089
18. Cheung AT, Chan MS, Ramanujam S, et al. Effects of poloxamer 188 treatment on sickle cell vaso-occlusive crisis: computer-assisted intravital microscopy study. J Investig Med 2004;52(6):402-6
19. Ballas SK, Files B, Luchtman-Jones L, et al. Safety of purified poloxamer 188 in sickle cell disease: Phase I study of a non-ionic surfactant in the management of acute chest syndrome. Hemoglobin 2004;28(2):85-102
20. Hoppe C, Kuypers F, Larkin S, et al. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol 2011;153(5):655-63
21. Field JJ, Ataga KI, Majerus EM, et al. A Phase I single ascending dose study of NKTT120 in stable adult sickle cell patients. Blood 2013;122(21):977
22. Field JJ, Nathan DG, Linden J. The role of adenosine signaling in sickle cell therapeutics. Hematol Oncol Clin North Am 2014;28(2):287-99
23. Solovey A, Somani A, Chen CS, et al. Interference with TNF alpha using longterm etanercept in S+S-Antilles sickle transgenic mice ameliorates abnormal endothelial activation, vasoocclusion, and pulmonary hypertension including its pulmonary arterial wall remodeling. Blood 2013;122(21):728
24. Howard J, Thein SL, Galacteros F, et al. Safety and tolerability of MP4CO: a dose escalation study in stable patients with sickle cell disease. Blood 2013;122(21):2205
25. Desai PC, Brittain JE, Jones SK, et al. A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thromb Res 2013;132(3):341-5
26. Wun T, Soulieres D, Frelinger AL, et al. A double-blind, randomized, multicenter Phase II study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol 2013;6:17
27. Belcher JD, Chen C, Nguyen J, et al. Heme triggers TLR4 signaling leading to endothelial cell activation and vasoocclusion in murine sickle cell disease. Blood 2014;123(3):377-90
28. Ghosh S, Adisa OA, Chappa P, et al. Extracellular hemin crisis triggers acute chest syndrome in sickle mice. J Clin Invest 2013;123(11):4809-20
29. Hanson MS, Xu H, Flewelen TC, et al. A novel hemoglobin-binding peptide reduces cell-free hemoglobin in murine hemolytic anemia. Am J Physiol Heart Circ Physiol 2013;304(2):H328-36
30. Olsson MG, Allhorn M, Bulow L, et al. Pathological conditions involving extracellular hemoglobin: molecular mechanisms, clinical significance, and novel therapeutic opportunities for alpha (1)-microglobulin. Antioxid Redox Signal 2012;17(5):813-46
31. Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA 2011;305(9):893-902
32. Morris CR, Kuypers FA, Lavrisha L, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica 2013;98(9):1375-82
33. Almeida CB, Scheiermann C, Jang JE, et al. Hydroxyurea and a cGMPamplifying agent have immediate benefits on acute vaso-occlusive events in sickle cell disease mice. Blood 2012;120(14):2879-88
34. De Falco S. Antiangiogenesis therapy: an update after the first decade. Korean J Intern Med 2014;29(1):1-11
35. Iwase T, Fu J, Yoshida T, et al. Sustained delivery of a HIF-1 antagonist for ocular neovascularization. J Control Release 2013;172(3):625-33
36. Casini G, Dal Monte M, Fornaciari I, et al. The beta-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases. Prog Retin Eye Res 2014;42:103-29
37. Impellizzeri D, Esposito E, Attley J, et al. Targeting inflammation: new therapeutic approaches in chronic kidney disease (CKD). Pharmacol Res 2014;81:91-102
38. Maguire JJ, Davenport AP. Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review Br J Pharmacol 2014;171(24):5555-72
39. Yang JJ, Tao H, Huang C, et al. Nuclear erythroid 2-related factor 2: a novel potential therapeutic target for liver fibrosis. Food Chem Toxicol 2013;59:421-7
40. Nakagawa A, Lui FE, Wassaf D, et al. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces ss erythrocyte sickling. ACS Chem Biol 2014;9(10):2318-25